Online Impact
Statistics from Altmetric.com
ARTICLE USAGE
Cited By
Article Information
Volume 9, Issue 2, pp. 199-209
PubMed
Published By
Print ISSN
Online ISSN
History
- Received May 25, 2018
- Revision received October 5, 2018
- Accepted November 15, 2018
- Published first November 21, 2018.
Article Versions
- Previous version (November 21, 2018 - 08:19).
- Previous version (January 25, 2019 - 05:44).
- You are viewing the most recent version of this article.
Copyright & Usage
©2018 American Association for Cancer Research.
Author Information
- Francisco Sanchez-Vega1,2,
- Jaclyn F. Hechtman3,
- Pau Castel2,
- Geoffrey Y. Ku4,
- Yaelle Tuvy4,
- Helen Won1,
- Christopher J. Fong1,2,
- Nancy Bouvier1,
- Gouri J. Nanjangud5,
- Joanne Soong3,
- Efsevia Vakiani3,
- Mark Schattner4,
- David P. Kelsen4,
- Robert A. Lefkowitz6,
- Karen Brown6,
- Mario E. Lacouture4,
- Marinela Capanu7,
- Marissa Mattar8,
- Besnik Qeriqi8,
- Fabiola Cecchi9,
- Yuan Tian9,
- Todd Hembrough9,
- Rebecca J. Nagy10,
- Richard B. Lanman10,
- Steven M. Larson6,
- Neeta Pandit-Taskar6,
- Heiko Schöder6,
- Christine A. Iacobuzio-Donahue3,
- David H. Ilson4,
- Wolfgang A. Weber6,
- Michael F. Berger1,2,3,
- Elisa de Stanchina8,
- Barry S. Taylor1,2,7,
- Jason S. Lewis6,
- David B. Solit1,2,4,
- Jorge A. Carrasquillo6,
- Maurizio Scaltriti2,3,
- Nikolaus Schultz1,2,7 and
- Yelena Y. Janjigian4,*
- 1Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
- 2Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
- 3Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
- 4Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York.
- 5Molecular Cytogenetics Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York.
- 6Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
- 7Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
- 8Antitumor Assessment Core Facility, Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
- 9NantOmics, Rockville, Maryland.
- 10Guardant Health, Inc., Redwood City, California.
- ↵*Corresponding Author:
Yelena Y. Janjigian, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, Division of Solid Tumor Oncology, 300 E 66th Street, Room 1033, New York, NY 10065. Phone: 646-888-4186; Fax: 646-888-4256; E-mail: janjigiy{at}mskcc.org
J.A. Carrasquillo, M. Scaltriti, N. Schultz, and Y.Y. Janjigian contributed equally to this article.
February 2019
Volume 9, Issue 2
Volume 9, Issue 2
EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer
Jump to section
Advertisement